pretty good results with Irinotecan plus gemcitabine in panc cancer

Discussion in 'Health and medical' started by Roger, Feb 7, 2004.

  1. Roger

    Roger Guest

    J Clin Oncol. 2002 Mar 1;20(5):1182-91.

    Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients
    with previously untreated advanced pancreatic cancer.

    H. Lee Moffitt Cancer Center, University of South Florida, Gastrointestinal Program Office, Tampa,
    FL 33612, USA.

    PURPOSE: This phase II, multicenter, open-label, single-arm study evaluated the efficacy and safety
    of irinotecan and gemcitabine as combination chemotherapy for previously untreated patients with
    unresectable or metastatic pancreatic cancer.

    PATIENTS AND METHODS: Patients received repeated 21-day cycles at starting doses of gemcitabine
    1,000 mg/m(2) over 30 minutes followed immediately by irinotecan 100 mg/m(2) over 90 minutes, both
    given intravenously on days 1 and 8. Patients were evaluated for objective tumor response, changes
    in the serum tumor marker CA 19-9, time to tumor progression (TTP), survival, and safety.

    RESULTS: Forty-five patients were treated. Eleven patients (24%) had 50% or greater reductions in
    tumor area. These were confirmed one cycle later in nine patients (response rate, 20%; 95%
    confidence interval, 8% to 32%). Among 44 patients with baseline CA 19-9 determinations, CA 19-9
    decreased during therapy in 22 patients (50%) and was reduced by 50% or more in 13 patients (30%).
    Median TTP [time to progression] was 2.8 months (range, 0.3 to 10.8 months). There were significant
    (P <.001) correlations between proportional changes in CA 19-9 and radiographic changes in tumor
    area with regard to extent of change (r =.67), timing of minimum on-study values (r
    =.85), and tumor progression (r =.89). Median survival was 5.7 months
    (range, 0.4 to 19.4+ months), and the 1-year survival rate was 27%. Severe toxicities were uncommon
    and primarily limited to grade 4 neutropenia (2%), grade 4 vomiting (2%), and grade 3 diarrhea (7%).

    CONCLUSION: Irinotecan/gemcitabine is a new combination that offers encouraging activity in terms of
    radiographic and CA 19-9 response and notable 1-year survival in pancreatic cancer. The regimen was
    well tolerated, with minimal grade 3 and 4 toxicities and excellent maintenance of planned dose-
    intensity.
     
    Tags:


  2. J

    J Guest

    Roger wrote:

    > CONCLUSION: Irinotecan/gemcitabine is a new combination that offers encouraging activity in terms
    > of radiographic and CA 19-9 response and notable 1-year survival in pancreatic cancer. The regimen
    > was well tolerated, with minimal grade 3 and 4 toxicities and excellent maintenance of planned dose-
    > intensity.

    Why are you "spamming" alt.support.cancer with all these? J
     
Loading...